NEW YORK (GenomeWeb News) – BioFocus and DiscoveRx have signed a co-marketing pact that allows BioFocus to offer screening services using DiscoveRx's assay technologies, BioFocus said today.

Under the agreement, BioFocus, based in Saffron Walden, UK, will offer to its customers DiscoverX's PathHunter beta-arrestin GPCR assays, HitHunter cAMP assays, and associated cell lines.

"The addition of the DiscoveRx GPCR product portfolio to BioFocus will enhance our assay development and screening platform,” Chris Newton, senior vice president at BioFocus, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.